RAPP · Categories · Form 4

RAPP - SEC Form 4 insider transactions

Rapport Therapeutics Inc. (RAPP) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for RAPP

• 11d
  Large owner Third Rock Ventures V, L.P. sold $743,753 worth of shares (18,572 units at $40.05) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 26d
  Large owner Third Rock Ventures V, L.P. sold $5,377,323 worth of shares (133,618 units at $40.24) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 28d
  Large owner Third Rock Ventures V, L.P. sold $11,094,906 worth of shares (276,513 units at $40.12) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 48d
  SEC Form 4 filed by Third Rock Ventures V, L.P.

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 48d
  SEC Form 4 filed by Yeleswaram Krishnaswamy

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 55d
  SEC Form 4 filed by Yeleswaram Krishnaswamy

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 60d
  SEC Form 4 filed by Yeleswaram Krishnaswamy

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 69d
  SEC Form 4 filed by Gault Cheryl

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 74d
  SEC Form 4 filed by Yeleswaram Krishnaswamy

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 91d
  Chief Operating Officer Gault Cheryl sold $58,265 worth of shares (2,014 units at $28.93), decreasing direct ownership by 1% to 169,914 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 109d
  Chief Executive Officer Ceesay Abraham sold $320,373 worth of shares (10,916 units at $29.35), decreasing direct ownership by 1% to 556,247 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 109d
  Chief Scientific Officer Bredt David sold $246,655 worth of shares (8,500 units at $29.02) and exercised 6,000 shares at a strike of $1.80, decreasing direct ownership by 0.63% to 393,075 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 124d
  SEC Form 4 filed by Chief Medical Officer Sevigny Jeffrey

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 124d
  SEC Form 4 filed by Chief Executive Officer Ceesay Abraham

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 124d
  SEC Form 4 filed by Chief Financial Officer Ignelzi Troy A.

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 124d
  SEC Form 4 filed by Chief Development Officer Yeleswaram Krishnaswamy

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 124d
  SEC Form 4 filed by Chief Scientific Officer Bredt David

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 124d
  SEC Form 4 filed by Chief Operating Officer Gault Cheryl

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 137d
  Chief Executive Officer Ceesay Abraham sold $285,071 worth of shares (10,916 units at $26.11), decreasing direct ownership by 1% to 562,080 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 143d
  Chief Scientific Officer Bredt David sold $228,132 worth of shares (8,500 units at $26.84), decreasing direct ownership by 2% to 395,575 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 154d
  Chief Scientific Officer Bredt David sold $197,338 worth of shares (6,567 units at $30.05) and gave a grant of 18,000 shares, decreasing direct ownership by 6% to 404,075 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 154d
  Chief Development Officer Yeleswaram Krishnaswamy was granted 9,000 shares and sold $85,342 worth of shares (2,840 units at $30.05), increasing direct ownership by 2% to 296,991 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 172d
  Chief Executive Officer Ceesay Abraham sold $323,508 worth of shares (10,916 units at $29.64), decreasing direct ownership by 1% to 567,913 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 174d
  Chief Scientific Officer Bredt David sold $255,130 worth of shares (8,500 units at $30.02), decreasing direct ownership by 2% to 392,642 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 189d
  Chief Operating Officer Gault Cheryl exercised 5,000 shares at a strike of $1.80 and sold $150,486 worth of shares (5,000 units at $30.10) (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 202d
  Chief Executive Officer Ceesay Abraham sold $275,047 worth of shares (10,916 units at $25.20), decreasing direct ownership by 1% to 573,746 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 202d
  Chief Scientific Officer Bredt David sold $214,091 worth of shares (8,500 units at $25.19), decreasing direct ownership by 2% to 401,142 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 235d
  Chief Scientific Officer Bredt David sold $219,196 worth of shares (8,500 units at $25.79), decreasing direct ownership by 2% to 409,642 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 235d
  Chief Executive Officer Ceesay Abraham sold $281,729 worth of shares (10,916 units at $25.81), decreasing direct ownership by 1.00% to 579,579 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 262d
  Chief Executive Officer Ceesay Abraham sold $2,011,197 worth of shares (76,420 units at $26.32), decreasing direct ownership by 7% to 585,412 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 264d
  Chief Scientific Officer Bredt David sold $205,649 worth of shares (8,500 units at $24.19), decreasing direct ownership by 2% to 418,142 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 271d
  Chief Operating Officer Gault Cheryl sold $191,650 worth of shares (5,000 units at $38.33) and exercised 5,000 shares at a strike of $1.80 (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 294d
  Chief Scientific Officer Bredt David sold $127,466 worth of shares (8,500 units at $15.00), decreasing direct ownership by 2% to 426,642 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 327d
  Chief Scientific Officer Bredt David sold $118,962 worth of shares (8,500 units at $14.00), decreasing direct ownership by 2% to 435,142 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Young Wendy B.

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Sanchez Ramiro

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Maraganore John

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Healy James

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Perez Robert J

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Silva Paul M

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  Chief Scientific Officer Bredt David sold $93,522 worth of shares (8,500 units at $11.00), decreasing direct ownership by 2% to 443,642 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Huber Reid M

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 355d
  SEC Form 4 filed by Director Paul Steven M

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 385d
  Chief Scientific Officer Bredt David sold $81,262 worth of shares (8,500 units at $9.56), decreasing direct ownership by 2% to 452,142 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 418d
  Chief Scientific Officer Bredt David sold $81,310 worth of shares (8,500 units at $9.57), decreasing direct ownership by 2% to 460,642 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 431d
  SEC Form 4 filed by Chief Medical Officer Sevigny Jeffrey

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 448d
  Chief Scientific Officer Bredt David sold $92,205 worth of shares (8,500 units at $10.85), decreasing direct ownership by 2% to 469,142 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 460d
  Chief Operating Officer Gault Cheryl was granted 13,987 shares, increasing direct ownership by 9% to 171,928 units (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 489d
  SEC Form 4 filed by Chief Financial Officer Ignelzi Troy A.

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 489d
  SEC Form 4 filed by Chief Scientific Officer Bredt David

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 489d
  SEC Form 4 filed by Chief Executive Officer Ceesay Abraham

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 489d
  SEC Form 4 filed by Chief Development Officer Yeleswaram Krishnaswamy

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 489d
  SEC Form 4 filed by Chief Operating Officer Gault Cheryl

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 578d
  SEC Form 4 filed by Director Young Wendy B.

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 578d
  SEC Form 4 filed by Director Perez Robert J

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 578d
  SEC Form 4 filed by Director Silva Paul M

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 578d
  SEC Form 4 filed by Director Sanchez Ramiro

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 728d
  Large owner Arch Venture Partners Xii, Llc converted options into 3,728,738 shares (SEC Form 4)

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 728d
  SEC Form 4 filed by Chief Medical Officer Galer Bradley S.

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)
• 728d
  SEC Form 4 filed by Chief Scientific Officer Bredt David

  4 - Rapport Therapeutics, Inc. (0002012593) (Issuer)

Other RAPP categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends